80 results on '"Vorinostat"'
Search Results
2. Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management
3. Design of SAHA-Loaded PLGA Nanoparticles Aimed for Use in Breast Cancer Combination Therapy
4. Histone Methyltransferases as a New Target for Epigenetic Action of Vorinostat
5. Selinexor assists vorinostat in inhibiting HDAC activity via promoting the accumulation of maspin in the nucleus of oral tongue squamous cell carcinoma cells
6. Epigenetic regulation and autophagy modulation debilitates insulin resistance associated Alzheimer’s disease condition in rats
7. Improved oral bioavailability of poorly water-soluble vorinostat by self-microemulsifying drug delivery system
8. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms
9. Treatment trials in Niemann-Pick type C disease
10. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer
11. Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines
12. Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways
13. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma
14. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
15. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent
16. Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation
17. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
18. Evaluation of Anti-Tumor Efficacy of Vorinostat Encapsulated Self-Assembled Polymeric Micelles in Solid Tumors
19. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
20. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer
21. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification
22. Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer
23. Co-delivery of Vorinostat and Etoposide Via Disulfide Cross-Linked Biodegradable Polymeric Nanogels: Synthesis, Characterization, Biodegradation, and Anticancer Activity
24. Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients
25. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro
26. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat
27. Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells
28. PU.1 regulates Alzheimer’s disease-associated genes in primary human microglia
29. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome
30. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
31. Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma
32. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
33. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
34. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
35. Vorinostat Modulates the Imbalance of T Cell Subsets, Suppresses Macrophage Activity, and Ameliorates Experimental Autoimmune Uveoretinitis
36. Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines
37. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents
38. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
39. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
40. Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
41. Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells
42. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
43. Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial
44. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience
45. Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage
46. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
47. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer
48. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
49. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
50. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.